je.st
news
Tag: liver
Scientists Grow Human Liver With Stem Cells in Mice, Give Hope to Humans
2013-07-05 20:15:29| Footwear - Topix.net
Scientists have been able to use stem cells to grow a functioning miniature human liver in mice, giving hope to thousands waiting for liver and other organ transplants.
Lawmakers to NY Docs: Screen All Baby Boomers for Deadly Liver Disease
2013-07-01 11:44:38| Footwear - Topix.net
New York could become the first state to mandate that doctors make testing for hepatitis C, a deadly and widespread liver disease, a routine part of healthcare for baby boomers.
Tags: baby
screen
disease
docs
Study: Drinking Coffee Could Lower Risk Of Rare Liver Disease
2013-05-22 05:27:26| Biotech - Topix.net
The Partnership At Drugfree.org describes caffeine as a psychoactive stimulant on their website , citing the Centers for Disease Control and Prevention in Atlanta and the National Institute on Drug Abuse as sources of information on the matter.
Tags: study
lower
risk
disease
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress
2013-04-23 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor that in preclinical evaluations has demonstrated a high barrier to resistance. Language: English Contact HTML: MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
updated
Merck to Present New Data on VICTRELIS (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
2013-04-08 16:37:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Mercks investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. Language: English Contact HTML: MerckMedia:Caroline Lappetito, 267-305-7369Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
international
present
meeting